|
---|
|
Advances in wearable devices have made it possible to deliver high-volume, high-viscosity biologics.
More diversified therapies and tighter payer budgets will challenge bio/pharma companies to think outside the industry.
Outsourcing analytics can be a cost-effective way for biopharma companies to adapt to new technologies and regulations.
A $5.5-million expansion at its Philadelphia, PA clinical supplies facility gives Catalent additional packaging and storage capacity.
A new study by the Business Research Company reveals prominent contract research organization outsourcing trends.
FDA sent a warning letter to Tris Pharma Inc. after investigators found the company had failed to properly investigate batch failures and establish quality control procedures.
Outsourcing analytics can be a cost-effective way for biopharma companies to adapt to new technologies and regulations.
FDA’s Center for Drug Evaluation and Research has published its second annual report on key safety programs and activities.
The agency has released new guidance on the development of new medication-assisted treatments for opioid dependence.
The new document answers questions regarding implementation of the ICH Q7 guidance on GMPs for APIs.